Gait Exoskeletons at
1/3 the Cost
of Western Brands
Clinical-grade lower-limb exoskeleton systems from China -- packaged, priced, and supported for the European distribution model.
- Complete portfolio: gait trainer, hip assist, and ankle/AFO devices
- 30-40% distributor margin vs €80K-€100K Western brand pricing
- ISO 13485 manufacturing partners · HS 8479.89 trade classification
- 20+ years B2B export experience · FOB/CIF terms with full documentation
A Purpose-Built B2B Model
We work exclusively with distributors and institutional buyers -- not individual patients. Every aspect of our offer is designed around your commercial reality.
Medical Device Distributors & Importers
Serving rehabilitation hospitals and neuro-rehab centers across Germany, Sweden, Denmark, Netherlands, and other European markets.
- Seeking differentiated products with 30-40% gross margin potential
- Want a trading partner who understands HS codes, documentation, and export logistics
- Looking for a complete lower-limb portfolio -- not just a single device
- Need staged entry: demo units first, larger orders once market fit is proven
Rehabilitation Hospitals & Neuro-Rehab Centers
Stroke units, SCI rehabilitation wards, geriatric rehab centers, and outpatient physiotherapy practices.
- Need robotic gait training but constrained by equipment budgets
- Looking for a complete pathway: early gait → corridor walking → ankle/foot drop management
- Want to increase patient throughput without adding therapist headcount
- Can access GaitExo systems through your local distribution partner
The Gait Exoskeleton Gap in Europe
Western brands have created a market -- but their pricing excludes the majority of mid-sized rehabilitation hospitals. That's the gap GaitExo is built to fill.
Why Adoption Stalls at Mid-Sized Hospitals
- Premium systems (EksoNR, ReWalk) are typically priced at €80K-€100K per unit, beyond the capital budget of most mid-sized rehab wards
- Manual gait therapy limits therapists to 4-8 supervised sessions per day per therapist -- a bottleneck that grows as patient volumes increase
- Most brands offer a single flagship device, not a full lower-limb pathway covering gait training, transition walking, and ankle management
A Practical Alternative for Distributors
- Offer clinical-grade gait training systems with FOB prices starting at €25K -- leaving room for 30-40% distributor margin while staying far below Western brand pricing
- Build package proposals combining gait trainer, hip assist, and ankle/AFO devices -- increasing deal size while covering the full rehabilitation pathway
- Export under HS 8479.89 as rehabilitation training equipment -- a practical import pathway that local advisors can build on as needed
A Complete Lower-Limb Rehabilitation Ecosystem
Three complementary device categories that together cover the full rehabilitation pathway -- from early standing and gait retraining through to community walking support.
Gait Training Exoskeleton
Intensive, repetitive gait retraining for stroke, SCI, and neurological rehabilitation patients. Overground and treadmill configurations.
Hip Assist Exoskeleton
Lightweight hip flexion support for corridor and community walking. Bridges the gap between intensive gait training and independent ambulation.
Ankle Assist & AFO Solutions
Powered and passive solutions for foot drop and ankle control during supervised rehabilitation and daily walking.
Trading & Partnership Model
A structured, low-risk path from first contact to regional partnership -- designed to reduce your commercial risk at every stage.
Market Fit & Configuration
We help you select suitable gait, hip, and ankle systems based on your hospital network, budget levels, and local reimbursement environment. We propose a starting configuration, not just a product list.
Trade & Compliance Pathway
Equipment exported as rehabilitation training devices under HS 8479.89. You and your regulatory advisors decide whether and when to pursue local medical device registration -- we provide full technical documentation to support that process.
Pilot → Regional Scale
Start with 1-2 demo units and initial small packages. After positive hospital feedback and first commercial deals, expand to larger orders and explore regional distribution agreements with us.
Responsibility statement: GaitExo acts as a trading and branding partner. We are not the local medical device registrant. Local classification, registration decisions, and clinical use protocols are managed by the importer and their regulatory advisors in accordance with national regulations. We provide technical documentation, ISO 13485 quality records, and usage guidance to support your pathway -- the registration decisions are yours to make.
Transparent Commercial Model for Distributors
We share pricing ranges openly so you can evaluate the opportunity before committing to a conversation. Exact figures depend on configuration and volume.
| Item | Indicative Range | Notes |
|---|---|---|
| Factory FOB price (gait trainer) | €25K - €40K per system | Depending on model and configuration |
| Factory FOB price (hip assist) | €12K - €20K per unit | Soft exosuit design |
| Factory FOB price (ankle/AFO) | €6K - €14K per unit | Powered and passive options |
| Typical hospital end-user price | €45K - €65K (gait trainer) | Distributor sets final pricing |
| Distributor gross margin (indicative) | 30 - 40% | Depends on configuration and negotiation |
| Western brand reference pricing | EksoNR, ReWalk, Hocoma |
All prices are indicative. Detailed quotes are provided after an initial discussion of your specific needs, volume, and market.
Research-Backed, Medically Manufactured
The systems we supply are developed and manufactured by Chinese partners with serious clinical and quality credentials -- not consumer robotics companies.
Research Collaboration
Manufacturing partners have established joint research programs with Chinese Academy of Sciences institutes, focusing on gait recognition, human-robot interaction, and sensor fusion for lower-limb rehabilitation.
ISO 13485 Quality System
All manufacturing partners operate under ISO 13485 medical device quality management systems, with dedicated assembly and testing lines, and rigorous component lifespan and safety validation processes.
Clinical Deployment Experience
Systems are already in active use across Chinese neuro-rehabilitation hospitals and centers for stroke, SCI, and other neurological conditions -- under professional supervision as clinical rehabilitation tools.
From Chinese Rehabilitation Settings
These are illustrative examples based on real deployment feedback. They are not clinical outcome claims -- individual results depend on patient profile, clinical protocols, and therapist practice.
Gait Trainer Deployment for Stroke & SCI Patients
A 60-bed neuro-rehabilitation ward integrated one gait training exoskeleton into their intensive therapy protocol for early-stage stroke and incomplete SCI patients. The system was used under physiotherapist supervision for repetitive, bodyweight-supported gait retraining.
Clinical team reported approximately 15-20 assisted gait cycles per session, compared to 8-10 with manual therapist support. Therapists noted reduced physical strain over an 8-week deployment period. (Based on clinical team feedback; individual patient outcomes vary.)
Hip Assist Devices for Transition-Phase Ambulation
Following intensive gait training, a rehabilitation center introduced hip assist exoskeletons to extend walking practice into longer corridor sessions and semi-independent ambulation. Patients in the 4-10 week post-acute phase were the primary users.
Patients were able to practice longer walking distances with reduced therapist physical involvement. The devices were reported to support patient confidence during the transition from supported to more independent walking. (Illustrative based on deployment feedback; not a clinical study.)
All case descriptions are based on real-world usage feedback from Chinese rehabilitation settings and are shared for illustrative purposes only. GaitExo makes no claims about specific clinical outcomes. Results depend on patient selection, clinical protocols, and local practice.
Common Questions from Distributors
Are you the manufacturer or a trading partner?
GaitExo is a trading and branding partner -- we are not the manufacturer. We work with selected Chinese manufacturers who meet our quality and documentation requirements, handle the full export process on your behalf, and manage all technical communication and documentation. You deal with one stable partner, not a factory directly.
Who is responsible for medical device registration in my country?
You are, as the local importer. GaitExo exports under HS 8479.89 as rehabilitation training equipment. Whether this needs to be registered as a medical device in your country -- and under which classification -- depends on your national regulations and intended use. We provide full technical documentation, ISO 13485 quality records, and regulatory support materials to help your process, but the registration decision and submission are yours to manage with your local regulatory advisors.
Can we start with a demo unit before committing to larger orders?
Yes -- this is our standard recommended starting point. We encourage a pilot of 1-2 units to validate market response, clinical acceptance, and practical logistics in your market before either side commits to larger volumes. Demo unit pricing, terms, and delivery timelines are discussed individually.
What is a typical lead time for delivery to Europe?
Standard lead time from order confirmation is 4-8 weeks, depending on product configuration and order volume. For pilot units, we work to expedite where possible. Sea freight to major European ports is our standard logistics approach; air freight can be arranged for urgent requirements at additional cost.
What does a realistic first year of partnership look like?
Most new distributors start with 1 pilot unit in weeks 1-4, use that for clinical demonstrations and initial hospital conversations over months 2-3, then place a first commercial order of 2-5 units once they have confirmed interest from 2-3 hospital accounts. The realistic Year 1 revenue target varies significantly by market and hospital network size -- we discuss this directly and honestly based on your specific situation, not with generic projections.
Ready to Explore a
Gait Exoskeleton Portfolio
for Your Market?
Tell us about your territory and hospital network. We'll propose a realistic starting package and pricing structure -- no generic pitch decks, just a direct conversation about your situation.
Tell us your territory, hospital network size, and product interests -- we'll send a targeted catalog and indicative pricing within 24 hours.
We can connect you with a local distributor or work directly with you to find the right partner in your country. Contact us to start that conversation.